

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

In re: Seroquel XR (Extended Release
Quetiapine Fumarate) Antitrust Litigation

Case No. 1:20-cv-01076-CFC

This Document Relates To:
All End-Payor Class Actions

~~PROPOSED~~ ORDER GRANTING CO-LEAD COUNSEL'S MOTION
FOR AN AWARD OF ATTORNEYS' FEES, REIMBURSEMENT OF
EXPENSES, AND GRANT OF SERVICE AWARDS TO THE CLASS
REPRESENTATIVES

WHEREAS, on March, 28, 2025, Co-Lead Counsel¹ for the End-Payor Plaintiffs² ("EPPs") filed a Motion for an Award of Attorneys' Fees, Reimbursement of Expenses, and Grant of Service Awards to the Class Representatives ("Attorneys' Fees Motion") pursuant to Rule 23(h) of the Federal Rules of Civil Procedure following the preliminary approval of the proposed class settlements among EPPs, defendants AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited

¹ Co-Lead Counsel are Grant & Eisenhofer P.A., Cohen Milstein Sellers & Toll PLLC, and Miller Shah LLP.

² The named "End-Payor Plaintiffs" or "EPPs" are: Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund; Law Enforcement Health Benefits, Inc.; the Mayor and City Council of Baltimore; Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C, and 137R; and the Uniformed Firefighters' Association of Greater New York Security Benefit Fund and the Retired Firefighters' Security Benefit Fund of the Uniformed Firefighters' Association (collectively, the "Class Representatives").

(collectively, “AstraZeneca”), and defendant Handa Pharmaceuticals, LLC (“Handa,” and together with AstraZeneca, “Defendants”); and

WHEREAS, on April 24, 2025, this Court held a hearing on Co-Lead Counsel’s Attorneys’ Fees Motion, and having carefully considered all the submissions, arguments, and applicable law, and with due deliberation thereon;

NOW, IT IS HEREBY ORDERED THAT:

1. This Order hereby incorporates by reference the definitions in the September 18, 2024 Settlement Agreement between EPPs and AstraZeneca (the “AstraZeneca Settlement Agreement”), Dkt. 768-1, and the September 19, 2024 Settlement Agreement between EPPs and Handa (the “Handa Settlement Agreement”), Dkt. 768-2, and all capitalized terms used and not otherwise defined herein shall have the meanings set forth therein.

2. Co-Lead Counsel have moved for an award of attorneys’ fees, reimbursement of costs and expenses, and services awards for the Class Representatives. Co-Lead Counsel request an award of attorneys’ fees in the amount of \$1,122,188.14 (representing 33⅓% of the Settlement Fund after deducting unreimbursed expenses), reimbursement of the reasonable costs and expenses incurred in the prosecution of this Action in the amount of \$2,108,435.59 (together with a proportionate share of the interest on both since the Settlement Amount were deposited in the Settlement Escrow Account), and service awards of \$10,000 to each

Class Representative. Such motion has been on the docket and otherwise publicly available since March 28, 2025.

3. Upon consideration of Co-Lead Counsel's petition for fees, costs, and expenses, Co-Lead Counsel hereby are awarded attorneys' fees totaling \$ 1,122,198.14 and costs and expenses totaling \$ 2,108,435.59, together with a proportionate share of the interest thereon from the date the funds were deposited in the Escrow Account until payment of such attorneys' fees, costs, and expenses, at the rate earned by the Settlement Fund. Such fees, costs, expenses, and interest are to be paid solely from the Settlement Fund and only if and after the Settlements become final in accordance with Paragraphs 40 and 45 of the AstraZeneca Settlement Agreement and Paragraphs 39 and 44 of the Handa Settlement Agreement.

4. Upon consideration of Co-Lead Counsel's petition for service awards for Class Representatives, each Class Representative hereby is awarded \$ 10,000, to be paid solely from the Settlement Fund and only if and after the Settlement becomes final in accordance with Paragraphs 40 and 45 of the AstraZeneca Settlement Agreement and Paragraphs 39 and 44 of the Handa Settlement Agreement.


5. Co-Lead Counsel have sole discretion to allocate and distribute such attorneys' fees, costs, and expenses among the various other Class Counsel that have

participated in this litigation. The Released Parties shall have no responsibility for, and no liability whatsoever with respect to, any allocation of attorneys' fees, expenses, costs, or service awards among Class Counsel and/or Class Representatives, nor with respect to any allocation of attorneys' fees, expenses, costs, or service awards to any other person or entity who may assert any claim thereto.

6. Co-Lead Counsel are authorized to pay attorneys' fees, costs, and expenses and distribute service awards authorized and approved by this Order upon entry of this Order. The attorneys' fees, costs, expenses, and service awards authorized and approved by this Order shall constitute full and final satisfaction of any and all claims that EPPs and any Class Member, and their respective counsel, may have or assert for reimbursement of fees, costs, expenses, and service awards, and End-Payor Plaintiffs and Class members shall not seek or demand payment of any fees, costs, expenses, and/or service awards from AstraZeneca or Handa other than from the Settlement Fund.

SO ORDERED:

Date: April 25, 2025



The Honorable Colm F. Connolly
Chief Judge, United States
District Court